SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer

SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer

Background: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape studies indicate that EGFR/HER2/RAS “pathway” act...

Full description

Bibliographic Details
Main Authors: Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Janet S. Winston, Rick J. Jansen, Carolyn F. O’Connor, Andrew J. Isbell, Minglei Bian, Rui Qin, Patricia T. Bassett, Virginia J. Hinson, Kimberly A. Dorsch, Brad W. Kirby, Robert E. Van Sciver, Angela M. Tang-Tan, Elizabeth A. Harden, David Z. Chang, Cynthia A. Allen, Roger R. Perry, Richard A. Hoefer, Amy H. Tang
Format: Article
Language:English
Published: Elsevier 2016-09-01
Series:EBioMedicine
Subjects:
Locally advanced and metastatic breast cancer
Neoadjuvant systemic therapies
Needle biopsies
The RAS pathway activation in breast cancer
SIAH E3 ligase
Clinicopathological predictors
And prognostic biomarkers
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396416303632

Internet

http://www.sciencedirect.com/science/article/pii/S2352396416303632

Similar Items